[
  {
    "ts": null,
    "headline": "Figma initiated, Okta upgraded: Wall Street's top analyst calls",
    "summary": "Figma initiated, Okta upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=6a5a64614c6e9cc9e9a6f9a701e748090179b31f8930d170f579e282d8924b08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756129009,
      "headline": "Figma initiated, Okta upgraded: Wall Street's top analyst calls",
      "id": 136508447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Figma initiated, Okta upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=6a5a64614c6e9cc9e9a6f9a701e748090179b31f8930d170f579e282d8924b08"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics",
    "summary": "Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.",
    "url": "https://finnhub.io/api/news?id=5949c51d9c6c49c56ad896fb2098f0d97a34ae17a6fab93304e4bbf7685a312d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756126320,
      "headline": "FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics",
      "id": 136508448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.",
      "url": "https://finnhub.io/api/news?id=5949c51d9c6c49c56ad896fb2098f0d97a34ae17a6fab93304e4bbf7685a312d"
    }
  }
]